[ { "key": "E48G6963", "version": 249, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/E48G6963", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/E48G6963", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/4U5W3XGS", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "E48G6963", "version": 249, "parentItem": "4U5W3XGS", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-10-03T04:39:47Z", "url": "http://link.springer.com/article/10.1007%2Fs40520-015-0335-2#/close", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "10.html", "md5": "4c99a65393ae2635f6ad94f0a010f4f0", "mtime": 1443847187000, "tags": [], "relations": {}, "dateAdded": "2015-10-03T04:39:47Z", "dateModified": "2015-10-03T04:39:47Z" } }, { "key": "4U5W3XGS", "version": 248, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/4U5W3XGS", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/4U5W3XGS", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Korkmaz et al.", "parsedDate": "2015-03-01", "numChildren": 1 }, "data": { "key": "4U5W3XGS", "version": 248, "itemType": "journalArticle", "title": "Liraglutide-related cholelithiasis", "creators": [ { "creatorType": "author", "firstName": "Hakan", "lastName": "Korkmaz" }, { "creatorType": "author", "firstName": "Mustafa", "lastName": "Araz" }, { "creatorType": "author", "firstName": "Samet", "lastName": "Alkan" }, { "creatorType": "author", "firstName": "Ersin", "lastName": "Akarsu" } ], "abstractNote": "", "publicationTitle": "Aging Clinical and Experimental Research", "publisher": "", "place": "", "date": "2015/03/01", "volume": "27", "issue": "5", "section": "", "partNumber": "", "partTitle": "", "pages": "751-753", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Aging Clin Exp Res", "DOI": "10.1007/s40520-015-0335-2", "citationKey": "", "url": "http://link.springer.com/article/10.1007/s40520-015-0335-2", "accessDate": "2015-10-03T04:39:41Z", "PMID": "", "PMCID": "", "ISSN": "1720-8319, 1720-8319", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "en", "libraryCatalog": "link.springer.com", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "Cholelithiasis", "type": 1 }, { "tag": "Geriatrics/Gerontology", "type": 1 }, { "tag": "Liraglutide", "type": 1 }, { "tag": "Ursodeoxycholic acid", "type": 1 } ], "collections": [], "relations": {}, "dateAdded": "2015-10-03T04:39:41Z", "dateModified": "2015-10-03T04:39:41Z" } }, { "key": "7WEHQNP6", "version": 247, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/7WEHQNP6", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/7WEHQNP6", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/7UZDZ3FM", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "7WEHQNP6", "version": 247, "parentItem": "7UZDZ3FM", "itemType": "attachment", "linkMode": "imported_url", "title": "ScienceDirect Snapshot", "accessDate": "2015-10-01T02:50:08Z", "url": "http://www.schres-journal.com/article/S0920-9964(08)00238-7/abstract", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "abstract.html", "md5": "1f3b563fd2bdf991048f34eb594598c7", "mtime": 1443667808000, "tags": [], "relations": {}, "dateAdded": "2015-10-01T02:50:08Z", "dateModified": "2015-10-01T02:50:08Z" } }, { "key": "7UZDZ3FM", "version": 246, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/7UZDZ3FM", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/7UZDZ3FM", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Lykkegaard et al.", "parsedDate": "2008-08", "numChildren": 1 }, "data": { "key": "7UZDZ3FM", "version": 246, "itemType": "journalArticle", "title": "The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance", "creators": [ { "creatorType": "author", "firstName": "Kirsten", "lastName": "Lykkegaard" }, { "creatorType": "author", "firstName": "Philip J.", "lastName": "Larsen" }, { "creatorType": "author", "firstName": "Niels", "lastName": "Vrang" }, { "creatorType": "author", "firstName": "Camilla", "lastName": "Bock" }, { "creatorType": "author", "firstName": "Troels", "lastName": "Bock" }, { "creatorType": "author", "firstName": "Lotte Bjerre", "lastName": "Knudsen" } ], "abstractNote": "Therapeutic use of atypical antipsychotic agents is often associated with weight gain and impaired glucose tolerance. The once-daily human GLP-1 analog liraglutide improves glycemic control and reduces body weight. We have investigated the ability of liraglutide to improve olanzapine-induced metabolic effects in female rats.\n\nFemale Sprague–Dawley rats were implanted with subcutaneous osmotic mini pumps for delivery of olanzapine (1.75 mg/24 h) or vehicle for 28 days (n = 20). After 14 days, ten animals from each group were given liraglutide (0.2 mg/kg) or vehicle twice daily for the remainder of the study. Compared to vehicle treated animals, olanzapine infusion for 4 weeks significantly increased end point cumulated food intake (667.3 ± 7.0 versus 593.2 ± 13.2g, p < 0.01), body weight (306.6 ± 4.2 versus 276.4 ± 3.6 g, p < 0.001), subcutaneous inguinal fat (3.4 ± 0.3 versus 1.9 ± 0.1 g, p < 0.001), mesenteric fat (3.1 ± 0.2 versus 1.7 ± 0.2g, p < 0.001), retroperitoneal fat (6.2 ± 0.6 versus 2.8 ± 0.3 g, p < 0.001), and impaired glucose tolerance, measured as total area under the glucose curve during an oral glucose tolerance test (1906 ± 66 versus 1770 ± 28 mM × min, p < 0.05). These olanzapine-induced elevations were significantly reduced by liraglutide (cumulated food intake: 601.8 ± 20.4 g, p < 0.01; body weight: 280.2 ± 5.6 g, p < 0.001; subcutaneous inguinal fat: 2.4 ± 0.2 g, p < 0.001; mesenteric fat: 1.8 ± 0.1 g, p < 0.001; retroperitoneal fat: 3.5 ± 0.4 g, p < 0.001; AUC: 1764 ± 32 mM × min, p < 0.05).\n\nIn conclusion, subcutaneous olanzapine infusion in female rats leads to weight gain and metabolic changes of which several are reversed following liraglutide treatment. It may therefore be relevant to study these effects of liraglutide in patients treated with atypically antipsychotics.", "publicationTitle": "Schizophrenia Research", "publisher": "", "place": "", "date": "August 2008", "volume": "103", "issue": "1–3", "section": "", "partNumber": "", "partTitle": "", "pages": "94-103", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Schizophrenia Research", "DOI": "10.1016/j.schres.2008.05.011", "citationKey": "", "url": "http://www.sciencedirect.com/science/article/pii/S0920996408002387", "accessDate": "2015-10-01T02:50:00Z", "PMID": "", "PMCID": "", "ISSN": "0920-9964", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "ScienceDirect", "callNumber": "", "rights": "", "extra": "", "tags": [ { "tag": "Atypical antipsychotics", "type": 1 }, { "tag": "Schizophrenia", "type": 1 }, { "tag": "Weight Loss", "type": 1 }, { "tag": "Weight gain", "type": 1 }, { "tag": "type 2 diabetes", "type": 1 } ], "collections": [], "relations": {}, "dateAdded": "2015-10-01T02:50:00Z", "dateModified": "2015-10-01T02:50:00Z" } }, { "key": "Q8ZIIJKU", "version": 245, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/Q8ZIIJKU", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/Q8ZIIJKU", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Mearns et al.", "parsedDate": "2015", "numChildren": 0 }, "data": { "key": "Q8ZIIJKU", "version": 245, "itemType": "journalArticle", "title": "Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis", "creators": [ { "creatorType": "author", "firstName": "E. S.", "lastName": "Mearns" }, { "creatorType": "author", "firstName": "W. J.", "lastName": "Saulsberry" }, { "creatorType": "author", "firstName": "C. M.", "lastName": "White" }, { "creatorType": "author", "firstName": "C. G.", "lastName": "Kohn" }, { "creatorType": "author", "firstName": "S.", "lastName": "Lemieux" }, { "creatorType": "author", "firstName": "A.", "lastName": "Sihabout" }, { "creatorType": "author", "firstName": "I.", "lastName": "Salamucha" }, { "creatorType": "author", "firstName": "C. I.", "lastName": "Coleman" } ], "abstractNote": "", "publicationTitle": "Diabetic Medicine", "publisher": "", "place": "", "date": "07/2015", "volume": "", "issue": "", "section": "", "partNumber": "", "partTitle": "", "pages": "n/a-n/a", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "", "DOI": "10.1111/dme.12837", "citationKey": "", "url": "http://doi.wiley.com/10.1111/dme.12837", "accessDate": "2015-10-01T02:14:27Z", "PMID": "", "PMCID": "", "ISSN": "07423071", "archive": "", "archiveLocation": "", "shortTitle": "Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes", "language": "en", "libraryCatalog": "CrossRef", "callNumber": "", "rights": "", "extra": "", "tags": [], "collections": [], "relations": {}, "dateAdded": "2015-10-01T02:14:27Z", "dateModified": "2015-10-01T02:14:27Z" } }, { "key": "P9X7FVFM", "version": 244, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/P9X7FVFM", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/P9X7FVFM", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/FFTVDPCI", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "P9X7FVFM", "version": 244, "parentItem": "FFTVDPCI", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-10-01T01:46:24Z", "url": "http://hinarilogin.research4life.org/uniquesigdiabetes.diabetesjournals.org/uniquesig0/content/63/10/3346", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "3346.html", "md5": "edb800fd0b3d05644d0d0670e675533a", "mtime": 1443663984000, "tags": [], "relations": {}, "dateAdded": "2015-10-01T01:46:24Z", "dateModified": "2015-10-01T01:46:24Z" } }, { "key": "GZ8UAI87", "version": 243, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/GZ8UAI87", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/GZ8UAI87", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/FFTVDPCI", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "numChildren": 0 }, "data": { "key": "GZ8UAI87", "version": 243, "parentItem": "FFTVDPCI", "itemType": "attachment", "linkMode": "imported_url", "title": "Full Text PDF", "accessDate": "2015-10-01T01:45:41Z", "url": "http://hinarilogin.research4life.org/uniquesigdiabetes.diabetesjournals.org/uniquesig0/content/63/10/3346.full.pdf", "note": "", "contentType": "application/pdf", "charset": "", "filename": "Beiroa et al. - 2014 - GLP-1 Agonism Stimulates Brown Adipose Tissue Ther.pdf", "md5": "5bfffb8dad0104b1bb4ba1089c668be2", "mtime": 1443663958000, "tags": [], "relations": {}, "dateAdded": "2015-10-01T01:45:41Z", "dateModified": "2015-10-01T01:45:58Z" } }, { "key": "HJT65DT2", "version": 242, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/HJT65DT2", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/HJT65DT2", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/FFTVDPCI", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "HJT65DT2", "version": 242, "parentItem": "FFTVDPCI", "itemType": "attachment", "linkMode": "linked_url", "title": "PubMed entry", "accessDate": "2015-10-01T01:45:41Z", "url": "http://www.ncbi.nlm.nih.gov/pubmed/24917578", "note": "", "contentType": "text/html", "charset": "", "tags": [], "relations": {}, "dateAdded": "2015-10-01T01:45:41Z", "dateModified": "2015-10-01T01:45:41Z" } }, { "key": "FFTVDPCI", "version": 242, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/FFTVDPCI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/FFTVDPCI", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Beiroa et al.", "parsedDate": "2014-10-01", "numChildren": 3 }, "data": { "key": "FFTVDPCI", "version": 242, "itemType": "journalArticle", "title": "GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK", "creators": [ { "creatorType": "author", "firstName": "Daniel", "lastName": "Beiroa" }, { "creatorType": "author", "firstName": "Monica", "lastName": "Imbernon" }, { "creatorType": "author", "firstName": "Rosalía", "lastName": "Gallego" }, { "creatorType": "author", "firstName": "Ana", "lastName": "Senra" }, { "creatorType": "author", "firstName": "Daniel", "lastName": "Herranz" }, { "creatorType": "author", "firstName": "Francesc", "lastName": "Villarroya" }, { "creatorType": "author", "firstName": "Manuel", "lastName": "Serrano" }, { "creatorType": "author", "firstName": "Johan", "lastName": "Fernø" }, { "creatorType": "author", "firstName": "Javier", "lastName": "Salvador" }, { "creatorType": "author", "firstName": "Javier", "lastName": "Escalada" }, { "creatorType": "author", "firstName": "Carlos", "lastName": "Dieguez" }, { "creatorType": "author", "firstName": "Miguel", "lastName": "Lopez" }, { "creatorType": "author", "firstName": "Gema", "lastName": "Frühbeck" }, { "creatorType": "author", "firstName": "Ruben", "lastName": "Nogueiras" } ], "abstractNote": "GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs on adipose tissue as well as the brain areas responsible for these interactions remain largely unknown. We found that central injection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BAT) thermogenesis and adipocyte browning independent of nutrient intake. The mechanism controlling these actions is located in the hypothalamic ventromedial nucleus (VMH), and the activation of AMPK in this area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning. The decreased body weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently explained by the suppression of food intake. In a longitudinal study involving obese type 2 diabetic patients treated for 1 year with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure. Although the results do not exclude the possibility that extrahypothalamic areas are also modulating the effects of GLP-1R agonists, the data indicate that long-acting GLP-1R agonists influence body weight by regulating either food intake or energy expenditure through various hypothalamic sites and that these mechanisms might be clinically relevant.", "publicationTitle": "Diabetes", "publisher": "", "place": "", "date": "10/01/2014", "volume": "63", "issue": "10", "section": "", "partNumber": "", "partTitle": "", "pages": "3346-3358", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Diabetes", "DOI": "10.2337/db14-0302", "citationKey": "", "url": "http://hinarilogin.research4life.org/uniquesigdiabetes.diabetesjournals.org/uniquesig0/content/63/10/3346", "accessDate": "2015-10-01T01:45:41Z", "PMID": "", "PMCID": "", "ISSN": "0012-1797, 1939-327X", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "en", "libraryCatalog": "hinarilogin.research4life.org", "callNumber": "", "rights": "", "extra": "PMID: 24917578", "tags": [], "collections": [], "relations": {}, "dateAdded": "2015-10-01T01:45:41Z", "dateModified": "2015-10-01T01:45:41Z" } }, { "key": "UWNSVJKV", "version": 241, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/UWNSVJKV", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/UWNSVJKV", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/9CXP7CJU", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "UWNSVJKV", "version": 241, "parentItem": "9CXP7CJU", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-10-01T01:42:47Z", "url": "http://diabetes.diabetesjournals.org/content/63/10/3346.long", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "3346.html", "md5": "1316e81ea8c2be1710d266869f1095b3", "mtime": 1443663767000, "tags": [], "relations": {}, "dateAdded": "2015-10-01T01:42:47Z", "dateModified": "2015-10-01T01:42:47Z" } }, { "key": "UX9VRR23", "version": 240, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/UX9VRR23", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/UX9VRR23", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/9CXP7CJU", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "UX9VRR23", "version": 240, "parentItem": "9CXP7CJU", "itemType": "attachment", "linkMode": "linked_url", "title": "PubMed entry", "accessDate": "2015-10-01T01:42:40Z", "url": "http://www.ncbi.nlm.nih.gov/pubmed/24917578", "note": "", "contentType": "text/html", "charset": "", "tags": [], "relations": {}, "dateAdded": "2015-10-01T01:42:40Z", "dateModified": "2015-10-01T01:42:40Z" } }, { "key": "JJ76WI2N", "version": 250, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/JJ76WI2N", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/JJ76WI2N", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "numChildren": 0 }, "data": { "key": "JJ76WI2N", "version": 250, "itemType": "attachment", "linkMode": "imported_file", "title": "liraglutide 2015.pdf", "accessDate": "", "url": "", "note": "", "contentType": "application/pdf", "charset": "", "filename": "liraglutide 2015.pdf", "md5": "c4f93e33f9ff720a948b5cf6944eeeb4", "mtime": 1443939919000, "tags": [], "collections": [], "relations": {}, "dateAdded": "2015-09-25T02:53:20Z", "dateModified": "2015-09-25T02:53:20Z" } }, { "key": "QBH2T5QI", "version": 234, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/QBH2T5QI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/QBH2T5QI", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/R5CQVGH2", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "numChildren": 0 }, "data": { "key": "QBH2T5QI", "version": 234, "parentItem": "R5CQVGH2", "itemType": "attachment", "linkMode": "imported_url", "title": "PubMed Central Full Text PDF", "accessDate": "2015-09-25T02:30:40Z", "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424381/pdf/ijo2014177a.pdf", "note": "", "contentType": "application/pdf", "charset": "", "filename": "Iepsen et al. - 2015 - Treatment with a GLP-1 receptor agonist diminishes.pdf", "md5": "5f98d97c7b457a8efdde58027ffb93e4", "mtime": 1443148243000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T02:30:40Z", "dateModified": "2015-09-25T02:30:44Z" } }, { "key": "R68228HP", "version": 233, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/R68228HP", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/R68228HP", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/R5CQVGH2", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "R68228HP", "version": 233, "parentItem": "R5CQVGH2", "itemType": "attachment", "linkMode": "linked_url", "title": "PubMed Central Link", "accessDate": "2015-09-25T02:30:40Z", "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424381/", "note": "", "contentType": "text/html", "charset": "", "tags": [], "relations": {}, "dateAdded": "2015-09-25T02:30:40Z", "dateModified": "2015-09-25T02:30:40Z" } }, { "key": "R5CQVGH2", "version": 233, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/R5CQVGH2", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/R5CQVGH2", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Iepsen et al.", "parsedDate": "2015-05", "numChildren": 2 }, "data": { "key": "R5CQVGH2", "version": 233, "itemType": "journalArticle", "title": "Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss", "creators": [ { "creatorType": "author", "firstName": "E W", "lastName": "Iepsen" }, { "creatorType": "author", "firstName": "J", "lastName": "Lundgren" }, { "creatorType": "author", "firstName": "C", "lastName": "Dirksen" }, { "creatorType": "author", "firstName": "J-EB", "lastName": "Jensen" }, { "creatorType": "author", "firstName": "O", "lastName": "Pedersen" }, { "creatorType": "author", "firstName": "T", "lastName": "Hansen" }, { "creatorType": "author", "firstName": "S", "lastName": "Madsbad" }, { "creatorType": "author", "firstName": "J J", "lastName": "Holst" }, { "creatorType": "author", "firstName": "S S", "lastName": "Torekov" } ], "abstractNote": "Background:\nRecent studies indicate that glucagon-like peptide (GLP)-1 inhibits appetite in part through regulation of soluble leptin receptors. Thus, during weight loss maintenance, GLP-1 receptor agonist (GLP-1RA) administration may inhibit weight loss-induced increases in soluble leptin receptors thereby preserving free leptin levels and preventing weight regain.\n\nMethods:\nIn a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2 mg per day). In case of weight gain, low-calorie diet products were allowed to replace up to two meals per day to achieve equal weight maintenance. Glucose tolerance and hormone responses were investigated before and after weight loss and after 52 weeks weight maintenance. Primary end points: increase in soluble leptin receptor plasma levels and decrease in free leptin index after 52 weeks weight loss maintenance.\n\nResults:\nSoluble leptin receptor increase was 59% lower; 2.1±0.7 vs 5.1±0.8 ng ml−1 (−3.0 (95% confidence interval (CI)=−0.5 to −5.5)), P<0.001 and free leptin index decrease was 43% smaller; −62±15 vs −109±20 (−47 (95% CI=−11 to −83)), P<0.05 with administration of GLP-1RA compared with control group. The 12% weight loss was successfully maintained in both the groups with no significant change in weight after 52 weeks follow-up. The GLP-1RA group had greater weight loss during the weight maintenance period (−2.3 kg (95% CI=−0.6 to −4.0)), and had fewer meal replacements per day compared with the control group (minus one meal per day (95% CI=−0.6 to −1)), P<0.001. Fasting glucose was decreased by an additional −0.2±0.1 mmol l−1 in the GLP-1RA group in contrast to the control group, where glucose increased 0.3±0.1 mmol l−1 to the level before weight loss (−0.5mmol l−1 (95% CI=−0.1 to −0.9)), P<0.005. Meal response of peptide PYY3–36 was higher at week 52 in the GLP-1RA group compared with the control group, P<0.05.\n\nConclusions:\nThe weight maintaining effect of GLP-1RAs may be mediated by smaller decrease in free leptin and higher PYY3–36 response. Low dose GLP-1RA therapy maintained 12% weight loss for 1 year and may prevent pre-diabetes in obesity.", "publicationTitle": "International Journal of Obesity (2005)", "publisher": "", "place": "", "date": "2015-05", "volume": "39", "issue": "5", "section": "", "partNumber": "", "partTitle": "", "pages": "834-841", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Int J Obes (Lond)", "DOI": "10.1038/ijo.2014.177", "citationKey": "", "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424381/", "accessDate": "2015-09-25T02:30:40Z", "PMID": "", "PMCID": "", "ISSN": "0307-0565", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "", "libraryCatalog": "PubMed Central", "callNumber": "", "rights": "", "extra": "PMID: 25287751\nPMCID: PMC4424381", "tags": [], "collections": [], "relations": {}, "dateAdded": "2015-09-25T02:30:40Z", "dateModified": "2015-09-25T02:30:40Z" } }, { "key": "927JF95A", "version": 232, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/927JF95A", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/927JF95A", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/NAKIC6BT", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "927JF95A", "version": 232, "parentItem": "NAKIC6BT", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-09-25T02:25:54Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12423/abstract", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "abstract.html", "md5": "df9e822f1db487bef75203d1bf8fd786", "mtime": 1443147954000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T02:25:54Z", "dateModified": "2015-09-25T02:25:54Z" } }, { "key": "NAKIC6BT", "version": 231, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/NAKIC6BT", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/NAKIC6BT", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Kanoski et al.", "parsedDate": "2015-03-01", "numChildren": 1 }, "data": { "key": "NAKIC6BT", "version": 231, "itemType": "journalArticle", "title": "Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms", "creators": [ { "creatorType": "author", "firstName": "S. E.", "lastName": "Kanoski" }, { "creatorType": "author", "firstName": "Z. Y.", "lastName": "Ong" }, { "creatorType": "author", "firstName": "S. M.", "lastName": "Fortin" }, { "creatorType": "author", "firstName": "E. S.", "lastName": "Schlessinger" }, { "creatorType": "author", "firstName": "H. J.", "lastName": "Grill" } ], "abstractNote": "Aim\n\nTo investigate the behavioural and intracellular mechanisms by which the glucagon like peptide-1 (GLP-1) receptor agonist, liraglutide, and leptin in combination enhance the food intake inhibitory and weight loss effects of either treatment alone.\n\n\nMethods\n\nWe examined the effects of liraglutide (a long-acting GLP-1 analogue) and leptin co-treatment, delivered in low or moderate doses subcutaneously (s.c.) or to the third ventricle, respectively, on cumulative intake, meal patterns and hypothalamic expression of intracellular signalling proteins [phosphorylated signal transducer and activator of transcription-3 (pSTAT3) and protein tyrosine phosphatase-1B (PTP1B)] in lean rats.\n\n\nResults\n\nA low-dose combination of liraglutide (25 µg/kg) and leptin (0.75 µg) additively reduced cumulative food intake and body weight, a result mediated predominantly through a significant reduction in meal frequency that was not present with either drug alone. Liraglutide treatment alone also reduced meal size; an effect not enhanced with leptin co-administration. Moderate doses of liraglutide (75 µg/kg) and leptin (4 µg), examined separately, each reduced meal frequency, cumulative food intake and body weight; only liraglutide reduced meal size. In combination these doses did not further enhance the anorexigenic effects of either treatment alone. Ex vivo immunoblot analysis showed elevated pSTAT3 in the hypothalamic tissue after liraglutide-leptin co-treatment, an effect which was greater than that of leptin treatment alone. In addition, s.c. liraglutide reduced the expression of PTP1B (a negative regulator of leptin receptor signalling), revealing a potential mechanism for the enhanced pSTAT3 response after liraglutide-leptin co-administration.\n\n\nConclusions\n\nCollectively, these results show novel behavioural and molecular mechanisms underlying the additive reduction in food intake and body weight after liraglutide-leptin combination treatment.", "publicationTitle": "Diabetes, Obesity and Metabolism", "publisher": "", "place": "", "date": "March 1, 2015", "volume": "17", "issue": "3", "section": "", "partNumber": "", "partTitle": "", "pages": "285-293", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Diabetes Obes Metab", "DOI": "10.1111/dom.12423", "citationKey": "", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12423/abstract", "accessDate": "2015-09-25T02:25:51Z", "PMID": "", "PMCID": "", "ISSN": "1463-1326", "archive": "", "archiveLocation": "", "shortTitle": "Liraglutide, leptin and their combined effects on feeding", "language": "en", "libraryCatalog": "Wiley Online Library", "callNumber": "", "rights": "© 2014 John Wiley & Sons Ltd", "extra": "", "tags": [ { "tag": "GLP-1", "type": 1 }, { "tag": "Obesity", "type": 1 }, { "tag": "Weight Loss", "type": 1 }, { "tag": "exendin-4", "type": 1 }, { "tag": "rat", "type": 1 }, { "tag": "synergy", "type": 1 } ], "collections": [], "relations": {}, "dateAdded": "2015-09-25T02:25:51Z", "dateModified": "2015-09-25T02:25:51Z" } }, { "key": "23QDBZA3", "version": 230, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/23QDBZA3", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/23QDBZA3", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/IZJ996WN", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "numChildren": 0 }, "data": { "key": "23QDBZA3", "version": 230, "parentItem": "IZJ996WN", "itemType": "attachment", "linkMode": "imported_url", "title": "Full Text PDF", "accessDate": "2015-09-25T02:23:25Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/pdf", "note": "", "contentType": "application/pdf", "charset": "", "filename": "Kapitza et al. - 2013 - Pharmacodynamic characteristics of lixisenatide on.pdf", "md5": "cf60586211219d5fbb40658998fa0602", "mtime": 1443147808000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T02:23:25Z", "dateModified": "2015-09-25T02:23:28Z" } }, { "key": "8ITT7N2J", "version": 230, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/8ITT7N2J", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/8ITT7N2J", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/IZJ996WN", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "8ITT7N2J", "version": 230, "parentItem": "IZJ996WN", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-09-25T02:23:27Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/abstract", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "abstract.html", "md5": "7ac3ede6ce952c080fea400ef4ad9938", "mtime": 1443147808000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T02:23:27Z", "dateModified": "2015-09-25T02:23:27Z" } }, { "key": "JMDGD2KN", "version": 227, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/JMDGD2KN", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/JMDGD2KN", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/8UKH7AS8", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "JMDGD2KN", "version": 227, "parentItem": "8UKH7AS8", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-09-25T02:15:48Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12423/abstract", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "abstract.html", "md5": "6a1eead8f94a5713f93a94f5d1bf53ac", "mtime": 1443147349000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T02:15:48Z", "dateModified": "2015-09-25T02:15:48Z" } }, { "key": "W49F65FI", "version": 225, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/W49F65FI", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/W49F65FI", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/ZIDNUV6W", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "W49F65FI", "version": 225, "parentItem": "ZIDNUV6W", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-09-25T01:28:19Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/abstract", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "abstract.html", "md5": "404ed0d325993d7ccb48c0c6bde2f787", "mtime": 1443144499000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T01:28:19Z", "dateModified": "2015-09-25T01:28:19Z" } }, { "key": "XDFS9M49", "version": 225, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/XDFS9M49", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/XDFS9M49", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/ZIDNUV6W", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "numChildren": 0 }, "data": { "key": "XDFS9M49", "version": 225, "parentItem": "ZIDNUV6W", "itemType": "attachment", "linkMode": "imported_url", "title": "Full Text PDF", "accessDate": "2015-09-25T01:28:16Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/pdf", "note": "", "contentType": "application/pdf", "charset": "", "filename": "Kapitza et al. - 2013 - Pharmacodynamic characteristics of lixisenatide on.pdf", "md5": "cf60586211219d5fbb40658998fa0602", "mtime": 1443144498000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T01:28:16Z", "dateModified": "2015-09-25T01:28:18Z" } }, { "key": "ZIDNUV6W", "version": 224, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/ZIDNUV6W", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/ZIDNUV6W", "type": "text/html" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "creatorSummary": "Kapitza et al.", "parsedDate": "2013-07-01", "numChildren": 2 }, "data": { "key": "ZIDNUV6W", "version": 224, "itemType": "journalArticle", "title": "Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin", "creators": [ { "creatorType": "author", "firstName": "C.", "lastName": "Kapitza" }, { "creatorType": "author", "firstName": "T.", "lastName": "Forst" }, { "creatorType": "author", "firstName": "H.-V.", "lastName": "Coester" }, { "creatorType": "author", "firstName": "F.", "lastName": "Poitiers" }, { "creatorType": "author", "firstName": "P.", "lastName": "Ruus" }, { "creatorType": "author", "firstName": "A.", "lastName": "Hincelin-Méry" } ], "abstractNote": "Aim\n\nAssess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin.\n\n\nMethods\n\nIn this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1–2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast. Primary endpoint was change in postprandial plasma glucose (PPG) exposure from baseline to day 28 during a breakfast test meal.\n\n\nResults\n\nLixisenatide reduced PPG significantly more than liraglutide [mean change in AUC0:30–4:30h: −12.6 vs. −4.0 h·mmol/L, respectively; p < 0.0001 (0:30 h = start of meal)]. Change in maximum PPG excursion was −3.9 mmol/l vs. −1.4 mmol/l, respectively (p < 0.0001). More lixisenatide-treated patients achieved 2-h PPG <7.8 mmol/l (69% vs. 29%). Changes in fasting plasma glucose were greater with liraglutide (−0.3 vs. −1.3 mmol/l, p < 0.0001). Lixisenatide provided greater decreases in postprandial glucagon (p < 0.05), insulin (p < 0.0001) and C-peptide (p < 0.0001). Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (−1.6 kg vs. −2.4 kg, respectively). Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or hypoglycaemia reported.\n\n\nConclusions\n\nOnce daily prebreakfast lixisenatide provided a significantly greater reduction in PPG (AUC) during a morning test meal versus prebreakfast liraglutide. Lixisenatide provided significant decreases in postprandial insulin, C-peptide (vs. an increase with liraglutide) and glucagon, and better gastrointestinal tolerability than liraglutide.", "publicationTitle": "Diabetes, Obesity and Metabolism", "publisher": "", "place": "", "date": "July 1, 2013", "volume": "15", "issue": "7", "section": "", "partNumber": "", "partTitle": "", "pages": "642-649", "series": "", "seriesTitle": "", "seriesText": "", "journalAbbreviation": "Diabetes Obes Metab", "DOI": "10.1111/dom.12076", "citationKey": "", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/abstract", "accessDate": "2015-09-25T01:28:16Z", "PMID": "", "PMCID": "", "ISSN": "1463-1326", "archive": "", "archiveLocation": "", "shortTitle": "", "language": "en", "libraryCatalog": "Wiley Online Library", "callNumber": "", "rights": "© 2013 Blackwell Publishing Ltd", "extra": "", "tags": [ { "tag": "GLP-1", "type": 1 }, { "tag": "metformin", "type": 1 }, { "tag": "pharmacodynamics", "type": 1 }, { "tag": "receptor", "type": 1 }, { "tag": "type 2 diabetes", "type": 1 } ], "collections": [], "relations": {}, "dateAdded": "2015-09-25T01:28:16Z", "dateModified": "2015-09-25T01:28:16Z" } }, { "key": "2FASXD44", "version": 225, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/2FASXD44", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/2FASXD44", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/NTG239P2", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } } }, "data": { "key": "2FASXD44", "version": 225, "parentItem": "NTG239P2", "itemType": "attachment", "linkMode": "imported_url", "title": "Snapshot", "accessDate": "2015-09-25T01:28:09Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/abstract", "note": "", "contentType": "text/html", "charset": "utf-8", "filename": "abstract.html", "md5": "3343c3544516f1811d434a07d163afb4", "mtime": 1443144489000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T01:28:09Z", "dateModified": "2015-09-25T01:28:09Z" } }, { "key": "SBXWPIPX", "version": 225, "library": { "type": "group", "id": 383005, "name": "Farmacología 2015", "links": { "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015", "type": "text/html" } } }, "links": { "self": { "href": "https://api.zotero.org/groups/383005/items/SBXWPIPX", "type": "application/json" }, "alternate": { "href": "https://www.zotero.org/groups/farmacologa_2015/items/SBXWPIPX", "type": "text/html" }, "up": { "href": "https://api.zotero.org/groups/383005/items/NTG239P2", "type": "application/json" } }, "meta": { "createdByUser": { "id": 2574425, "username": "BryanPAacios", "name": "", "links": { "alternate": { "href": "https://www.zotero.org/bryanpaacios", "type": "text/html" } } }, "numChildren": 0 }, "data": { "key": "SBXWPIPX", "version": 225, "parentItem": "NTG239P2", "itemType": "attachment", "linkMode": "imported_url", "title": "Full Text PDF", "accessDate": "2015-09-25T01:28:03Z", "url": "http://onlinelibrary.wiley.com/doi/10.1111/dom.12076/pdf", "note": "", "contentType": "application/pdf", "charset": "", "filename": "Kapitza et al. - 2013 - Pharmacodynamic characteristics of lixisenatide on.pdf", "md5": "cf60586211219d5fbb40658998fa0602", "mtime": 1443144487000, "tags": [], "relations": {}, "dateAdded": "2015-09-25T01:28:03Z", "dateModified": "2015-09-25T01:28:07Z" } } ]